Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort Study
Our findings indicate that toxicities, clinical events, and responses evolve differently in patients receiving ven/aza compared with that of 7+3 regimen. ML-based predictive models were shown to be a feasible strategy for CDS in both forms of AML treatment. If validated with larger and more diverse data sets, these findings could offer valuable insights for developing AML-CDS tools that leverage posttreatment clinical data.
Authors
- Justin Dale (ORCID: https://orcid.org/0009-0008-6879-9767)
- Nazmul Islam (ORCID: https://orcid.org/0009-0008-0609-7655)
- Craig T. Jordan (ORCID: https://orcid.org/0000-0003-0869-3465)
- Jamie S. Reuben (ORCID: https://orcid.org/0000-0002-5940-4224)
- Clayton A. Smith (ORCID: https://orcid.org/0000-0001-6478-4244)
- Karan Sapiah (ORCID: https://orcid.org/0009-0006-0992-4033)
- Frank R. Markson (ORCID: https://orcid.org/0009-0005-4026-3838)
- James W. Coates (ORCID: https://orcid.org/0009-0007-9417-0762)
Institutions
- The Medical Center of Aurora (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- JMIR Cancer
- Published
- 2024-08-21
- DOI
- https://doi.org/10.2196/54740
- Citations
- 5
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 2.27